Brian Werth

Has grant

Associate Professor

United States

Research Interests

Explore related searches

Professors in United States Professors in Microbiology Microbiology professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Brian Werth is an Associate Professor at the University of Washington School of Pharmacy in the United States. His research focuses on antimicrobial resistance, particularly in relation to methicillin-resistant Staphylococcus aureus, the interactions between various antibiotics, and the utilization of fatty acids by bacteria. Recent articles by Dr. Werth explore topics such as the emergence of antibiotic resistance, pharmacodynamics of antimicrobial agents, and high-throughput lipidomic analysis.

Recent Grants

Grant: Close

Contribution of altered lipid metabolism to resistance to cell envelope-targeting antimicrobials in MRSA

Open Date: 2018-08-15

Close Date: 2022-07-31

Grant: Close

Resistance Selection Potential of the Long Acting Lipoglycopeptides Dalbavancin and Oritavancin

Open Date: 2018-05-01

Close Date: 2020-04-30

Articles (12)

Year:

2025

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2020

Collaborators (6)

Hari Polenakovik

Wright State University

UNITED STATES

View details

Rutan Zhang

University of Washington

UNITED STATES

View details

Libin Xu

Associate Professor

University of Washington

UNITED STATES

View details

Jessina McGregor

Associate Professor

Oregon State University

UNITED STATES

View details

Alan Gross

Clinical Associate Professor

University of Chicago

UNITED STATES

View details

Francis Alonzo

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Brian Werth

Research Interests

Explore related searches

Contact this professor

About

Recent Grants

Articles (12)

Simulated exposures of oritavancin in in vitro pharmacodynamic models select for methicillin-resistant Staphylococcus aureus with reduced susceptibility to oritavancin but minimal cross-resistance or seesaw effect with other antimicrobials

Reporting behaviors and perceptions toward the National Healthcare Safety Network antimicrobial use (AU) and antimicrobial resistance (AR) modules

Elucidating the impact of bacterial lipases, human serum albumin, and FASII inhibition on the utilization of exogenous fatty acids by Staphylococcus aureus

High-throughput analysis of lipidomic phenotypes of methicillin-resistant Staphylococcus aureus by coupling in situ 96-well cultivation and HILIC-ion mobility-mass spectrometry

Emergence of Dalbavancin, Vancomycin, and Daptomycin Nonsusceptible Staphylococcus aureus in a Patient Treated With Dalbavancin: Case Report and Isolate Characterization

New Perspectives on Antimicrobial Agents: Long-Acting Lipoglycopeptides

Evolution of cefiderocol resistance in Stenotrophomonas maltophilia using in vitro serial passage techniques

Identification of a novel tedizolid resistance mutation in rpoB of MRSA after in vitro serial passage

Dalbavancin exposure in vitro selects for dalbavancin-non-susceptible and vancomycin-intermediate strains of methicillin-resistant Staphylococcus aureus

Synergy Between Beta-Lactams and Lipo-, Glyco-, and Lipoglycopeptides, Is Independent of the Seesaw Effect in Methicillin-Resistant Staphylococcus aureus

Varied Contribution of Phospholipid Shedding From Membrane to Daptomycin Tolerance in Staphylococcus aureus

Occurrence of cross-resistance and β-lactam seesaw effect in glycopeptide-, lipopeptide- and lipoglycopeptide-resistant MRSA correlates with membrane phosphatidylglycerol levels

Collaborators (6)

Hari Polenakovik

Rutan Zhang

Libin Xu

Jessina McGregor

Alan Gross

Francis Alonzo

Make your next move.